CTCL stands for cutaneous T-cell lymphoma, a group of non-Hodgkin lymphomas involving malignant T cells that initially affect the skin. Skin lesions often begin as rash-like patches and may progress to plaques or tumors as disease advances. The condition includes subtypes such as mycosis fungoides and Sezary syndrome.
Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06854653 |
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL |
RECRUITING | PHASE2 |
| NCT06470451 |
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL |
RECRUITING | PHASE3 |
| NCT05879458 |
Ritlecitinib in CTCL |
TERMINATED | PHASE2 |
| NCT04171791 |
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) |
COMPLETED | PHASE1 |
| NCT04087629 |
StrataCTX® as a Steroid Sparing Device |
RECRUITING | NA |
| NCT03240211 |
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03239392 |
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL |
COMPLETED | PHASE1/PHASE2 |
| NCT02757248 |
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL |
WITHDRAWN | PHASE1 |
| NCT02556463 |
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors |
TERMINATED | PHASE1 |
